Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SABS - US78397T2024 - Common Stock

3.98 USD
-0.02 (-0.5%)
Last: 1/16/2026, 8:00:01 PM
3.98 USD
0 (0%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, SABS scores 3 out of 10 in our fundamental rating. SABS was compared to 525 industry peers in the Biotechnology industry. While SABS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SABS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year SABS has reported negative net income.
  • SABS had a negative operating cash flow in the past year.
  • In the past 5 years SABS reported 4 times negative net income.
  • In multiple years SABS reported negative operating cash flow during the last 5 years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • SABS has a better Return On Assets (-11.65%) than 83.24% of its industry peers.
  • Looking at the Return On Equity, with a value of -12.94%, SABS belongs to the top of the industry, outperforming 86.86% of the companies in the same industry.
Industry RankSector Rank
ROA -11.65%
ROE -12.94%
ROIC N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

  • SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SABS has more shares outstanding than it did 1 year ago.
  • SABS has a worse debt/assets ratio than last year.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • SABS has an Altman-Z score of 5.37. This indicates that SABS is financially healthy and has little risk of bankruptcy at the moment.
  • SABS has a better Altman-Z score (5.37) than 73.90% of its industry peers.
  • SABS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • SABS's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. SABS outperforms 44.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 5.37
ROIC/WACCN/A
WACC8.84%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • SABS has a Current Ratio of 10.50. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
  • SABS's Current ratio of 10.50 is amongst the best of the industry. SABS outperforms 83.05% of its industry peers.
  • SABS has a Quick Ratio of 10.50. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
  • SABS has a Quick ratio of 10.50. This is amongst the best in the industry. SABS outperforms 83.05% of its industry peers.
Industry RankSector Rank
Current Ratio 10.5
Quick Ratio 10.5
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

  • SABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.62%, which is quite impressive.
  • Looking at the last year, SABS shows a very negative growth in Revenue. The Revenue has decreased by -92.42% in the last year.
  • Measured over the past years, SABS shows a very negative growth in Revenue. The Revenue has been decreasing by -72.10% on average per year.
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
Revenue 1Y (TTM)-92.42%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SABS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.98% yearly.
  • The Revenue is expected to grow by 125.90% on average over the next years. This is a very strong growth
EPS Next Y45.12%
EPS Next 2Y35.71%
EPS Next 3Y23.52%
EPS Next 5Y13.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-24.65%
Revenue Next 5Y125.9%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SABS's earnings are expected to grow with 23.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.71%
EPS Next 3Y23.52%

More info and screens

0

5. Dividend

5.1 Amount

  • SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (1/16/2026, 8:00:01 PM)

After market: 3.98 0 (0%)

3.98

-0.02 (-0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners59.15%
Inst Owner Change0%
Ins Owners1.87%
Ins Owner Change13.15%
Market Cap189.49M
Revenue(TTM)114.70K
Net Income(TTM)-21.37M
Analysts86.15
Price Target9.56 (140.2%)
Short Float %2.16%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.34%
Min EPS beat(2)-34.25%
Max EPS beat(2)70.94%
EPS beat(4)2
Avg EPS beat(4)20.03%
Min EPS beat(4)-34.25%
Max EPS beat(4)70.94%
EPS beat(8)4
Avg EPS beat(8)-35.61%
EPS beat(12)7
Avg EPS beat(12)-25.29%
EPS beat(16)10
Avg EPS beat(16)-40.08%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-76.57%
Min Revenue beat(4)-100%
Max Revenue beat(4)-6.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.13%
PT rev (3m)6.13%
EPS NQ rev (1m)-14.64%
EPS NQ rev (3m)62.86%
EPS NY rev (1m)8.01%
EPS NY rev (3m)11.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1652.03
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.65%
ROE -12.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.5
Quick Ratio 10.5
Altman-Z 5.37
F-Score3
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)828.01%
Cap/Sales(3y)14.46%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
EPS Next Y45.12%
EPS Next 2Y35.71%
EPS Next 3Y23.52%
EPS Next 5Y13.98%
Revenue 1Y (TTM)-92.42%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-24.65%
Revenue Next 5Y125.9%
EBIT growth 1Y16.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-178.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-183.73%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SABS.


What is the valuation status for SABS stock?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


What is the profitability of SABS stock?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for SAB BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of SAB BIOTHERAPEUTICS INC (SABS) is expected to grow by 45.12% in the next year.